# Use of Indocyanine Green (ICG) for the Diagnosis of Biliary Atresia

> **NCT07513038** · PHASE1,PHASE2 · RECRUITING · sponsor: **Boston Children's Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Biliary Atresia

## Interventions

- **DRUG:** Indocyanine Green (ICG)

## Key facts

- **NCT ID:** NCT07513038
- **Lead sponsor:** Boston Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2026-08
- **Final completion:** 2026-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07513038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07513038, "Use of Indocyanine Green (ICG) for the Diagnosis of Biliary Atresia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07513038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*